Adverse effects of bosutinib exposure at conception or during pregnancy in humans cannot be excluded, particularly if therapy is not interrupted upon recognition of pregnancy. Contraceptive use is recommended for female patients receiving bosutinib, and patients should be made aware of the potential risks associated with bosutinib use during pregnancy.
Keyphrases
- pregnancy outcomes
- end stage renal disease
- chronic myeloid leukemia
- pregnant women
- ejection fraction
- chronic kidney disease
- newly diagnosed
- human health
- peritoneal dialysis
- emergency department
- preterm birth
- risk assessment
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- patient reported
- replacement therapy